News Articles http://www.pharmaceuticalonline.com/ 12/5/2008 2:27:46 AM The FTS ThermoJet from SP Industries, Inc. is a precision-controlled temperature forcing system designed to rapidly change the temperature of a product or device under test. http://www.pharmaceuticalonline.com/article.mvc/Reliability-Through-Temperature-Cycling-0001?atc~c=771+s=773+r=001+l=a 12/5/2008 2:27:46 AM Roche recently announced that the U.S. Food and Drug Administration (FDA) has provided further guidance on the requirements for the Biologics License Application (BLA) for ACTEMRA® (tocilizumab), the first interleukin-6 (IL-6) receptor-inhibiting monoclonal antibody studied for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA). http://www.pharmaceuticalonline.com/article.mvc/Roche-And-FDA-Agree-On-Pathway-Towards-US-0001?atc~c=771+s=773+r=001+l=a 12/4/2008 11:37:00 PM This year's first place prize at the annual TrackWise® Innovation Awards went to Vetter Pharma-Fertigung GmbH & Co. KG for its outstanding implementation of Sparta System's software solution. http://www.pharmaceuticalonline.com/article.mvc/Vetter-Wins-TrackWise-Innovation-Award-0001?atc~c=771+s=773+r=001+l=a 12/4/2008 3:24:00 PM Research and Markets has announced the addition of John Wiley and Sons Ltd's new report "International IT Regulations and Compliance: Quality Standards in the Pharmaceutical and Regulated Industries" to their offering. This book aims to bring together current thinking on the implementation of standards and regulations in relation to IT for a wide variety of industries. http://www.pharmaceuticalonline.com/article.mvc/Quality-Standards-In-Pharmaceutical-Handbook-0001?atc~c=771+s=773+r=001+l=a 12/4/2008 5:00:00 AM CytRx Corporation (NASDAQ: CYTR) today unveiled its corporate strategy to focus its internal resources on the clinical development of oncology drug candidates tamibarotene and INNO-206, which the Company believes offer the greatest mix of near-term and medium-term revenue potential among its clinical assets. http://www.pharmaceuticalonline.com/article.mvc/CytRx-Unveils-Clinical-Development-Plan-0001?atc~c=771+s=773+r=001+l=a 12/3/2008 8:30:00 AM Exco InTouch, the leading mobile messaging provider for the pharmaceutical industry, announces that its text messaging technology ATLAS™ has been selected by Pfizer, one of the world's leading pharmaceutical companies to enhance the efficacy of its patient recruitment and retention in Phase I clinical trials. http://www.pharmaceuticalonline.com/article.mvc/Pfizer-Selects-Exco-InTouch-To-Enhance-0001?atc~c=771+s=773+r=001+l=a 12/3/2008 5:08:00 AM Isogen, a contract development and manufacturing organization for sterile filling, announced it has retained a strategic financial partner to help it expand operations to meet the global biopharma demand for Isogen's services. http://www.pharmaceuticalonline.com/article.mvc/Isogen-Retains-Strategic-Partner-Sheridan-0001?atc~c=771+s=773+r=001+l=a 12/3/2008 4:54:00 AM NanoVector, Inc. announced today that it has licensed the plant virus nanoparticle drug delivery system developed by Professors' Stefan Franzen and Steven Lommel from North Carolina State University. http://www.pharmaceuticalonline.com/article.mvc/NanoVector-to-Commercialize-First-Biologic-Na-0001?atc~c=771+s=773+r=001+l=a 12/2/2008 8:00:00 AM WuXi PharmaTech (Cayman) Inc., a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, recently announced it will dedicate its Philadelphia facility to the Company's expanding biologics testing, cell banking and cell therapy services, and as of December 31, 2008, WuXi will discontinue its U.S. biologics manufacturing operations. In conjunction, approximately 100 biologics manufacturing and supporting positions at the Philadelphia facility will be eliminated through workforce reduction and employee attrition. http://www.pharmaceuticalonline.com/article.mvc/WuXi-PharmaTech-Will-Focus-US-Operations-on-L-0001?atc~c=771+s=773+r=001+l=a 12/2/2008 6:09:00 AM MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report providing critical strategic insight for pharma and biotech companies with a stake in the market for Parkinson's disease (PD) therapies. This report, entitled Thought Leader Insight & Analysis -- Parkinson's Disease, is based on 9 interviews conducted with PD experts from the US (6) and Europe (3). http://www.pharmaceuticalonline.com/article.mvc/New-Report-Provides-Expert-Analysis-Of-Recent-0001?atc~c=771+s=773+r=001+l=a 12/2/2008 5:37:00 AM Symetix introduces the Optyx®SG/P optical inspection system designed specifically for tablets. With a new, integrated dust abatement feature and new KeyWare® application software for tablets, OptyxSG/P automatically inspects coated and uncoated tablets at high production speeds to remove defects and foreign tablets (rogues) from the product stream. Automating tablet inspection with OptyxSG/P assures the highest product quality while reducing labor costs. http://www.pharmaceuticalonline.com/article.mvc/Symetix-Introduces-OptyxregSGP-For-Tablets-0001?atc~c=771+s=773+r=001+l=a 12/2/2008 5:27:00 AM MonoSol Rx, the developers of PharmFilm® technology and a drug delivery company specializing in dissolving thin film pharmaceutical products, and Strativa Pharmaceuticals, the proprietary products division of Par Pharmaceutical Companies, Inc. , recently announced the successful completion of all pivotal bioequivalence studies for a thin film formulation of ondansetron. The ondansetron thin film product is being developed for the prevention of chemotherapy-induced nausea and vomiting, prevention of nausea and vomiting associated with radiotherapy, and post-operative nausea and vomiting. http://www.pharmaceuticalonline.com/article.mvc/Monosol-Rx-Successfully-Completes-Pivotal-0001?atc~c=771+s=773+r=001+l=a 12/2/2008 5:16:00 AM NicOx S.A. recently announced it has signed an agreement with DSM for the commercial manufacture and supply of naproxcinod drug substance (or API, active pharmaceutical ingredient). Naproxcinod is NicOx' lead investigational product and the first compound in the Cyclooxygenase-Inhibiting Nitric Oxide-Donating (CINOD) class of anti-inflammatory agents, which recently achieved positive results in the third pivotal phase 3 study in osteoarthritis patients. http://www.pharmaceuticalonline.com/article.mvc/NicOx-Signs-Agreement-With-DSM-For-The-0001?atc~c=771+s=773+r=001+l=a 12/2/2008 5:08:00 AM AccuDial Pharmaceutical announced recently that the Brazilian Patent and Trademark Office has issued patent No. 0108453-4, relating to a device for calculating therapeutically correct doses of liquid medications based on a patient's weight instead of age. http://www.pharmaceuticalonline.com/article.mvc/Brazilian-Patent-Office-Issues-Patent-For-0001?atc~c=771+s=773+r=001+l=a 12/2/2008 4:43:00 AM Eurofins AvTech Laboratories (AvTech), located in Portage, Michigan, is pleased to announce the Director of Business Development, Jeff Moran. Jeff will lead the business development team and enhance client relations through communication, marketing and strategy development by partnering with clients to get their drug products to market faster. http://www.pharmaceuticalonline.com/article.mvc/Eurofins-AvTech-Announces-Director-Of-0001?atc~c=771+s=773+r=001+l=a 12/2/2008 4:29:00 AM In its special 50th anniversary issue (September 2008), Applied Spectroscopy paid tribute to a groundbreaking paper which heralded the birth of a solid-state approach to chemical imaging. http://www.pharmaceuticalonline.com/article.mvc/Malvern-director-groundbreaking-research-0003?atc~c=771+s=773+r=001+l=a 12/2/2008 4:01:00 AM Thomas Davidson, Ph.D., has joined Ricerca as the director of toxicology and pharmacology. Dr. Davidson is responsible for the work performed by Ricerca study directors, peer review of toxicological reports and ensuring on-time delivery of these reports. http://www.pharmaceuticalonline.com/article.mvc/Ricerca-Director-Of-Toxicology-Pharmacology-0001?atc~c=771+s=773+r=001+l=a 12/2/2008 12:44:00 AM A collection of online educational materials are now available for free to consumers to help fend off the dangers of contaminated or counterfeit drugs. Unveiled today by the Partnership for Safe Medicines, "Consumer Resources" is designed to help consumers ensure the safety of their prescription drugs and includes guides on safely purchasing medicines online and how to save money without compromising drug safety. http://www.pharmaceuticalonline.com/article.mvc/Partnership-For-Safe-Medicines-Arms-Public-0001?atc~c=771+s=773+r=001+l=a 12/1/2008 4:05:00 AM Tigermed Consulting Co., Ltd, a leading Contract Research Organization (CRO) in China, announced that it has established a subsidiary, Hunan Tigermed Xiangya Drug R&D Ltd, with Central South University (CSU). The establishment of Tigermed Xiangya marks Tigermed's participation in the construction of a nationwide first-rate Phase I Clinical Laboratory, and further substantiates Tigermed's service ability in drug pre-clinical studies and pharmaceutical analysis. This new cooperation allows Tigermed to provide more extensive and comprehensive outsourcing clinical services for Multinational Pharmaceutical Corporations and Local Research Institutions in the research and development of innovative drugs. http://www.pharmaceuticalonline.com/article.mvc/Tigermed-Sets-Up-Subsidiary-Hunan-Tigermed-0001?atc~c=771+s=773+r=001+l=a 12/1/2008 3:56:00 AM China Medicine Corporation (BULLETIN BOARD: CHME) ("China Medicine" or "the Company"), a leading developer and distributor of prescription and over the counter pharmaceuticals, traditional Chinese medicines (TCM), nutritional and dietary supplements, and medical devices and medical formulations today announced that the Company was awarded GSP (Good Supply Practice for Pharmaceutical Products) certification from the Guangdong Food and Drug Administration (Guangdong FDA). http://www.pharmaceuticalonline.com/article.mvc/China-Medicine-Corporation-Awarded-GSP-0001?atc~c=771+s=773+r=001+l=a 12/1/2008 3:48:00 AM